To characterize the risk factors associated with neonatal thrombocytopenia among pregnant women with immune thrombocytopenic purpura (ITP). STUDY DESIGN: We reviewed the records of ITP patients who delivered during 2006-2016 at our medical center. RESULTS: Of 253 pregnancies, median maternal age at diagnosis was 29 [25][26][27][28][29][30][31][32][33] years, 222 (87.7%) had previously-diagnosed ITP and 31 (12.3%) were diagnosed with new-onset ITP during pregnancy. Baseline characteristics were comparable between the groups except for a higher proportion of nulliparity among those with new-onset disease (P¼0.002). Maternal nadir platelet count was significantly lower among those with new-onset compared to previously diagnosed ITP (median 62 X 10 9 /L vs. 81 X 10 9 /L, P¼0.005). Neonatal thrombocytopenia (<150 X 10 9 /L) was encountered in 24 (9.5%) pregnancies, and required treatment in 12 (50%) of them. Neonatal platelet count was directly correlated with maternal platelet count at delivery (r¼0.23, P¼0.01), with significantly lower maternal platelet count among those whose newborns experienced thrombocytopenia (P<0.001). Neonatal thrombocytopenia followed a higher proportion of pregnancies of women with new-onset than previously diagnosed ITP (22.6% vs. 7.7%, P¼0.02). In multivariate analysis, the presence of new-onset ITP (odds ratio [95% CI]: 4.88 (1.68, 14.16), P¼0.004) was the only independent predictor of the development of neonatal thrombocytopenia. CONCLUSION: Neonatal thrombocytopenia presented following almost one-tenth of pregnancies with ITP. New pregnancy-onset disease was the only prognostic marker for neonatal thrombocytopenia. This finding could contribute to risk stratification and individualized patient management.
824 Maternal congenital heart defects and long-term cardiovascular morbidity of the offspring OBJECTIVE: Due to advances in medical care available for patients with congenital heart disease (CHD), these patients now have a longer life span. As a result, the number of pregnancies of mothers with CHD has increased. The purpose of the current study was to examine a possible association between being born to a mother with CHD and long-term cardiovascular morbidity of the offspring. STUDY DESIGN: A population-based cohort analysis was performed including all singleton deliveries occurring between years 1991-2014 at a single tertiary medical center.The primary exposure was defined as being born to a mother with CHD. Offspring of mothers without CHD comprised the comparison (unexposed) group. The main outcome evaluated was cardiovascular morbidity of the offspring up to the age of 18 years. A Kaplan-Meier survival curve was used to compare cumulative cardiovascular morbidity incidence. A Cox proportional hazards model was conducted to control for confounders. RESULTS: During the study period 242,342 deliveries met the inclusion criteria, of which 0.2% (n¼ 368) were of mothers who had CHD. Long-term cardiovascular morbidity was comparable between offspring to women with and without CHD (1.1% vs. 0.6%, respectively, p¼0.298; Table) . However, offspring of mothers with CHD had higher rates of hypertensive disorders during childhood (0.5% vs. 0.1%; p¼0.021). The Kaplan-Meier survival curve did not demonstrate a significantly higher cumulative incidence of cardiovascular morbidity in offspring of women with CHD ( Figure, log rank p¼0.251). In the Cox regression model, while controlling for confounders such as maternal age, preterm birth, gestational diabetes mellitus and hypertensive disorders of pregnancy, delivery of a neonate to mother with CHD was not found to be independently associated with long-term cardiovascular morbidity of the offspring. CONCLUSION: Offspring of women who have congenital heart disease are not at an increased risk for long-term cardiovascular morbidity. 
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